ASCO
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
Fishermangents
- Site Admin
- Posts: 529
- Joined: Thu Dec 03, 2015 3:39 pm
Re: ASCO
You're right, Bio. It is part of the communication path and will also be supporitve for the enrolment of patients for the clinical trials. For me that's important enough, certainly with an authorblock of 18 great specialists and JnJ as co-author....
This is what I posted on 19 April about my expectations for ASCO:
======================
There will be no presentation of preliminary results of IMbark, as that is not aloud for the type of session Tefferi is in. Here are the rules for so called Trials In Progress Sessions (TPS):
Per ASCO, the following information is not acceptable in a Trials in Progress abstract:
* Any preliminary data including toxicity, response rate, pharmacokinetic, or correlative analyses. NOTE: Abstracts including results or preliminary data will be rejected without further review.
Per ASCO, the following information is acceptable in a Trials in Progress abstract:
* Scientific background/rationale for the trial.
* Preclinical and/or earlier-phase clinical data that has already been publically presented or published may be included with references. The Trials in Progress session should not be used to present preclinical or earlier-phase clinical data for the first time.
* Trial design and statistical methods, highlighting any novel aspects of the design
* Treatment or intervention planned
* Major eligibility criteria, highlighting unusual aspects
* Correlative studies of particular interest
* Current enrollment without providing results or endpoints
* Enrollment must have already begun or have been completed with no data analysis available by the submission deadline of February 2, 2016.
* Phase II studies may report, “8 of planned 32 patients have been enrolled” or “Prespecified activity goal for the first stage of accrual was met; second stage accrual began in January 2016.”
* Clinical trial registry number (required)
==================
This is what I posted on 19 April about my expectations for ASCO:
======================
There will be no presentation of preliminary results of IMbark, as that is not aloud for the type of session Tefferi is in. Here are the rules for so called Trials In Progress Sessions (TPS):
Per ASCO, the following information is not acceptable in a Trials in Progress abstract:
* Any preliminary data including toxicity, response rate, pharmacokinetic, or correlative analyses. NOTE: Abstracts including results or preliminary data will be rejected without further review.
Per ASCO, the following information is acceptable in a Trials in Progress abstract:
* Scientific background/rationale for the trial.
* Preclinical and/or earlier-phase clinical data that has already been publically presented or published may be included with references. The Trials in Progress session should not be used to present preclinical or earlier-phase clinical data for the first time.
* Trial design and statistical methods, highlighting any novel aspects of the design
* Treatment or intervention planned
* Major eligibility criteria, highlighting unusual aspects
* Correlative studies of particular interest
* Current enrollment without providing results or endpoints
* Enrollment must have already begun or have been completed with no data analysis available by the submission deadline of February 2, 2016.
* Phase II studies may report, “8 of planned 32 patients have been enrolled” or “Prespecified activity goal for the first stage of accrual was met; second stage accrual began in January 2016.”
* Clinical trial registry number (required)
==================
-
Fishermangents
- Site Admin
- Posts: 529
- Joined: Thu Dec 03, 2015 3:39 pm
Re: ASCO
Maybe they believe imetelstat/telomrease inhibition is a relevant topic?